Prostate cancer: epidemiology, current diagnostic trends and stratification of risk groups

In the structure of malignant neoplasm morbidity in men worldwide in 2020, prostate cancer (PCa) ranked second, second only to neoplasms ofthe trachea, bronchi and lung.Currently, oncourologists have a large arsenal of methods forthe treatment of prostate cancer, however,there are often problems in examining the patient and determining the stage ofthe disease. The choice oftreatmenttactics is based on stratification of patients into low-, intermediate-, and high-risk groups based on the results of prostate palpation, prostate-specific antigen level, Gleason sum, scintigraphy results, and prostate MRI. This review presents modern methods of diagnostics of prostate cancer and recommendations on stratification of patients in risk groups of progression..